Alphatec Holdings, Inc. (NASDAQ:ATEC) Receives Consensus Recommendation of "Buy" from Brokerages

Key Points

• Alphatec Holdings, Inc. (NASDAQ:ATEC) received an average analyst rating of "Buy" from six research firms, with a 1-year price target consensus of $18.50.
• General Counsel Tyson Eliot Marshall and EVP Craig E. Hunsaker sold shares recently, indicating a 3.96% and 3.45% decrease in their ownership respectively.
• The company reported a quarterly earnings per share (EPS) of $0.02, surpassing the consensus estimate by $0.08, with revenues increasing by 27.5% year-over-year.

Shares of Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) have been assigned a consensus recommendation of "Buy" from the six analysts that are covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $18.50.

Several equities research analysts have commented on the stock. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target on the stock in a research report on Monday, June 16th. Barclays reaffirmed an "overweight" rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research note on Monday, August 4th. Canaccord Genuity Group reaffirmed a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Friday, August 1st. Finally, Wall Street Zen raised Alphatec from a "hold" rating to a "buy" rating in a research note on Sunday.

Insider Transactions at Alphatec

In related news, EVP Craig E. Hunsaker sold 10,876 shares of the business's stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $15.33, for a total value of $166,729.08. Following the completion of the sale, the executive vice president owned 1,389,142 shares of the company's stock, valued at approximately $21,295,546.86. The trade was a 0.78% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, General Counsel Tyson Eliot Marshall sold 18,092 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were sold at an average price of $14.91, for a total value of $269,751.72. Following the completion of the sale, the general counsel directly owned 438,331 shares of the company's stock, valued at approximately $6,535,515.21. The trade was a 3.96% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 506,284 shares of company stock worth $7,579,535. 20.90% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alphatec

Several large investors have recently made changes to their positions in ATEC. Comerica Bank grew its stake in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after buying an additional 1,248 shares in the last quarter. Osterweis Capital Management Inc. acquired a new stake in Alphatec in the 2nd quarter worth approximately $37,000. Larson Financial Group LLC acquired a new stake in Alphatec in the 1st quarter worth approximately $54,000. Nisa Investment Advisors LLC lifted its holdings in Alphatec by 22.4% in the 2nd quarter. Nisa Investment Advisors LLC now owns 5,714 shares of the medical technology company's stock worth $63,000 after purchasing an additional 1,045 shares during the last quarter. Finally, Lazard Asset Management LLC acquired a new stake in Alphatec in the 4th quarter worth approximately $76,000. Institutional investors own 66.35% of the company's stock.

Alphatec Stock Performance

Shares of NASDAQ ATEC traded down $0.45 during midday trading on Friday, reaching $15.35. 2,030,274 shares of the company traded hands, compared to its average volume of 1,961,376. Alphatec has a 52 week low of $4.88 and a 52 week high of $16.70. The stock has a 50-day moving average price of $13.67 and a 200 day moving average price of $12.02. The company has a debt-to-equity ratio of 23.22, a current ratio of 2.88 and a quick ratio of 1.77. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -13.58 and a beta of 1.02.

Alphatec (NASDAQ:ATEC - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $0.08. Alphatec had a negative net margin of 24.33% and a negative return on equity of 1,657.19%. The business had revenue of $185.54 million for the quarter, compared to analysts' expectations of $178.85 million. During the same period in the previous year, the business earned ($0.29) earnings per share. The company's revenue was up 27.5% on a year-over-year basis. Alphatec has set its FY 2025 guidance at EPS. Sell-side analysts anticipate that Alphatec will post -1.08 earnings per share for the current fiscal year.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.